I. Brenkel

TL;DR: It is confirmed that women with thrombophilia are at risk of developing venous thromboembolism and complications in pregnancy, however, despite the increase in relative risk, the absolute risk of VTE and adverse outcomes remains low.

TL;DR: A systematic review of the literature on VTE and thrombophilia in women using oral oestrogen preparations and patients undergoing major orthopaedic surgery and the effectiveness of prophylaxis found homozygous carriers of this mutation are 34 times more likely to develop VTE in pregnancy than non-carriers.

TL;DR: The findings of this study support the presence of interaction between thrombophilia and venous thromboembolism among women taking oral contraceptives and hormone replacement therapy and further studies are required to establish with greater confidence the associations of these.

TL;DR: Selective thrombophilia screening based on previous personal and/or family history of venous thromboembolism was more cost‐effective than universal screening in all the patient groups evaluated.